Semaglutide

If You’ve Been Eating Right and the Weight Still Isn’t Moving

Here’s what that usually means. It’s not a discipline problem. It’s not that you haven’t found the right diet. For a large proportion of people who struggle with persistent weight, the issue is physiological — a combination of appetite signalling that doesn’t work the way it should, hormonal patterns that favour fat storage, and a food environment engineered to override satiety.

Semaglutide works on the first part of that problem directly. It mimics a hormone your gut naturally releases after eating — a hormone that signals to your brain that you’re full, slows down digestion, and helps your body manage blood sugar. The lab-made version is engineered to last a full week from a single injection, rather than the few minutes the natural hormone survives. That sustained signal is what produces the appetite reduction most users notice within the first one to two weeks. [REF:1]

This is not a supplement. It is not a metabolism booster. It is a prescription medicine — the same active ingredient in Ozempic and Wegovy — with a clinical trial program covering over 45,000 human subjects and some of the most rigorous weight loss data ever published. [REF:1] [REF:2]

✅  FACT-CHECK  Sources: Wilding et al. (2021) STEP 1 Trial, NEJM 384(11):989-1002 [REF:1]; Lincoff et al. (2023) SELECT Trial, NEJM [REF:2]. Mechanism description reflects approved prescribing information and peer-reviewed pharmacological literature. 45,000+ figure covers SUSTAIN, STEP, PIONEER, and SELECT trial programs combined.

What Semaglutide Actually Is

Semaglutide is a GLP-1 receptor agonist. GLP-1 stands for glucagon-like peptide-1 — a hormone your gut releases after eating. Its job in the body is to tell the brain you’ve had enough food, slow the rate at which your stomach empties, and signal the pancreas to release insulin in response to glucose.

The natural version of this hormone lasts about two minutes in your bloodstream. Semaglutide is a modified version of that hormone — 31 amino acids with a fatty acid chain attached — engineered to survive for approximately seven days. That’s why it works as a once-weekly injection. [REF:1]

While you’re using it, your body’s own GLP-1 signalling takes a back seat. The effects are driven by the medication. When you stop, they reverse — the appetite suppression goes away, and the weight typically returns. The STEP 1 extension study showed approximately two-thirds of weight lost was regained within one year of stopping. [REF:1] This isn’t a failure of the medication — it’s how it works. Semaglutide is a long-term tool, not a short course.

The three names you’ll see in Australia

The active ingredient is the same in all three. The brand and approved use differ:

Ozempic®	Injectable. Approved for type 2 diabetes. PBS-listed for T2DM. Any GP can prescribe. Manufactured by Novo Nordisk.
Wegovy®	Injectable. Approved for weight management (obesity). PBS-listed from July 2024. Same drug, higher dose range.
Rybelsus®	Oral tablet (daily). Approved for type 2 diabetes. PBS-listed for T2DM. Bioavailability is much lower than injectable (~0.4–1% vs ~89% SubQ).

✅  FACT-CHECK  Brand approvals sourced from TGA.gov.au and FDA.gov. PBS listing dates sourced from PBAC decisions. Bioavailability figures from approved prescribing information [REF:3].

Legal Status in Australia — The Exact Position

Semaglutide is legal in Australia with a valid prescription from a registered GP or specialist. You do not need a referral to an endocrinologist — any GP can prescribe it.

TGA Schedule	Schedule 4 (S4 POM) — Prescription Only Medicine. TGA-approved. Source: TGA Scheduling Secretariat, tga.gov.au — verified 24/02/2026
WADA Status	NOT PROHIBITED. Semaglutide does not appear on the WADA Prohibited List 2025. Competitive athletes may use it without a Therapeutic Use Exemption. Source: wada-ama.org/prohibited-list — verified 24/02/2026
GP Prescribing	Yes — any GP can prescribe. Endocrinologist referral not required.
PBS Listed	Yes — Ozempic (T2DM), Wegovy (obesity from July 2024), Rybelsus (T2DM). PBS script significantly reduces cost.
Compounded	Available through Australian compounding pharmacies. Compounded semaglutide is legal when prescribed by an authorised practitioner.

⚠️  IMPORTANT  Semaglutide cannot be purchased legally without a valid Australian prescription. Do not source it through grey market channels — product quality and concentration cannot be verified, and legal risk rests with the buyer.

✅  FACT-CHECK  TGA Schedule 4 status confirmed against TGA Scheduling Secretariat. WADA non-prohibition confirmed against WADA Prohibited List 2025. PBS listing dates confirmed against PBAC decisions. All verified 24/02/2026.

What to Expect — Honest Timelines from Clinical Trial Data

Most sites either overstate results or bury the caveats. Here is what the STEP 1 trial — the largest semaglutide weight loss trial, 1,961 participants, 68 weeks — actually showed, alongside what a realistic experience looks like. [REF:1]

Week 1–2	Appetite suppression is noticeable for most people. Food noise — the constant background thinking about food — decreases. Nausea is common and expected at this stage. It typically improves as the body adjusts.
Week 4–8	Measurable weight loss begins. Most people see 3–5% of body weight reduction by week 8. Energy may feel lower initially — this is normal during caloric restriction.
Week 12–16	Results become visible. Cardiovascular improvements begin showing on blood work. The titration schedule is usually reaching maintenance doses by this point.
Week 16–24	Approaching peak effect at maintenance dose. STEP 1 showed ~15% average total body weight loss at 68 weeks for the 2.4mg/week group. Individual results vary significantly.
Minimum commitment	12 weeks to properly assess. Most clinical data is at 52–68 weeks. This is not a 4-week trial — under-committing produces under-results.

The honest context: 15–17% average weight loss across a trial population means some people lose significantly more, some significantly less. The trial included people who exercised and maintained a caloric deficit alongside the medication. Semaglutide is not a replacement for dietary discipline — it is a tool that makes dietary discipline physiologically easier to sustain.

✅  FACT-CHECK  Timeline and outcome data sourced from Wilding et al. (2021) STEP 1 Trial, NEJM 384(11):989-1002 [REF:1]. 15–17% weight loss figure reflects trial average at 68 weeks for 2.4mg maintenance dose group. Individual results vary.

Dosing in Australia — The Titration Schedule

Semaglutide is titrated slowly to minimise nausea. The titration schedule below is the standard protocol used in clinical trials and approved prescribing information. Your GP may adjust this based on your response. [REF:3]

Starting dose	0.25mg once weekly — weeks 1–4. This dose has no meaningful weight loss effect. It exists to let your body adjust to the medication before the therapeutic dose begins.
Dose escalation	0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg weekly. Increase every 4 weeks if tolerated.
Maintenance dose	2.4mg once weekly (Wegovy for weight loss). 1mg or 2mg weekly (Ozempic for T2DM).
Route	Subcutaneous injection once weekly (Ozempic/Wegovy auto-injector pen). No reconstitution required — pre-filled pen.
Oral option	Rybelsus tablet — daily, taken on an empty stomach. Bioavailability is much lower than injectable. Not recommended for weight loss purposes.
Vial/pen size	★ 5mg vials for compounded. At 0.5mg/wk titration: 5mg = 10 weeks. At 2.4mg/wk maintenance: 5mg = ~2 weeks.
Storage	Pre-filled pen: refrigerate before first use, then room temp ≤30°C for up to 56 days. Compounded: refrigerate 2–8°C, use within 4–6 weeks of reconstitution.

ℹ️  NOTE  Dosing information is for educational purposes only. Your prescribing practitioner will determine your specific dose, titration schedule, and duration based on your individual health profile.

✅  FACT-CHECK  Titration schedule sourced from approved semaglutide prescribing information (Ozempic/Wegovy PI) [REF:3]. Vial duration estimates based on standard compounding pharmacy vial sizes. Storage specifications from manufacturer prescribing information.

What It Costs in Australia

PBS script (T2DM — Ozempic)	$180–350 AUD per month. Requires a T2DM diagnosis. Significantly lower than private script cost.
PBS script (obesity — Wegovy)	PBS-listed from July 2024. Eligibility criteria apply — confirm current PBS eligibility with your GP.
Private script (weight loss)	$400–900 AUD per month. No T2DM diagnosis required. Cost varies by brand and pharmacy.
Compounded semaglutide	$150–300 AUD per month. Requires a prescription from an authorised practitioner. Cost savings are significant but quality verification depends on the compounding pharmacy.

The cost difference between PBS and private script is substantial. If you have a T2DM diagnosis, a PBS prescription for Ozempic is significantly more affordable. If you’re using it purely for weight management without a T2DM diagnosis, you’ll pay private script prices unless Wegovy PBS eligibility applies to your situation.

These are 2025 market estimates from the Australian compounding pharmacy market. Prices are subject to change.

Side Effects — What the Trial Data Shows

Nausea is the most common side effect and the one most likely to affect your first few weeks. It’s not a sign something is wrong — it’s the mechanism working. Semaglutide slows gastric emptying, and nausea is a direct result of that. For most people it improves significantly after the first 4–8 weeks as the body adjusts.

Nausea	20–44% of trial participants. Most common in first 4–8 weeks. Usually improves. Eating smaller meals and avoiding high-fat food reduces severity.
Diarrhoea	15–30%. Often linked to the gastric emptying changes. Hydration is important.
Vomiting	8–24%. More common at higher doses. Slow titration reduces this.
Constipation	10–24%. Less common than nausea but persistent for some users.
Abdominal pain	6–11%. Usually mild.
Headache	14%. Often linked to reduced caloric intake in early weeks.

Serious risks to know before starting

⚠️  IMPORTANT  Thyroid C-cell tumours: Semaglutide carries a boxed warning for thyroid C-cell tumours based on rodent studies. No confirmed human signal has emerged after 6+ years of post-market use. It is contraindicated in people with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2). Discuss your family history with your GP before starting. [REF:3]

Other serious considerations:

• Pancreatitis: Rare. Discontinue and seek medical attention if you experience severe abdominal pain that doesn’t resolve.
• Pregnancy: Category X — contraindicated. Discontinue at least 2 months before planned conception.
• Drug interactions: All oral medications may have delayed absorption due to slowed gastric emptying. This includes oral contraceptives, levothyroxine, and warfarin. Inform your GP of all medications you take.
• Hypoglycaemia risk: Only relevant if combined with insulin or sulfonylureas. Semaglutide alone does not cause hypoglycaemia.

✅  FACT-CHECK  Side effect frequencies sourced from Wilding et al. (2021) STEP 1 Trial [REF:1]. Boxed warning text sourced from approved prescribing information [REF:3]. Contraindications verified against current TGA-approved prescribing information.

What the Research Shows — The Actual Evidence Base

Semaglutide has the most robust evidence base of any compound on this site. Evidence Grade A. Over 45,000 human subjects across the SUSTAIN, STEP, PIONEER, and SELECT trial programs. Here are the trials that matter.

STEP 1 (2021)	n=1,961. 68 weeks. 2.4mg/week vs placebo. ~15% average body weight reduction in treatment group. Primary weight loss efficacy trial. Published NEJM. [REF:1]
SELECT (2023)	n=17,604. Cardiovascular outcomes in overweight/obese adults without diabetes. 20% reduction in major cardiovascular events. The largest semaglutide trial to date. Published NEJM. [REF:2]
STEP 1 extension	Weight regain after stopping: ~2/3 of weight lost was regained within 1 year of discontinuation. Confirms long-term use is required to maintain results. [REF:1]
SUSTAIN program	Multiple trials for T2DM management. Established the diabetes indication that preceded the weight loss indication.
FLOW trial (ongoing)	Kidney disease outcomes. Adding to the evidence base for semaglutide beyond weight loss.

What the research does NOT support

• Permanent weight loss after stopping treatment — the evidence is the opposite
• Use in pregnancy — Category X, contraindicated
• Use in under-18s for weight loss
• Use without accompanying dietary changes — all trials involved dietary counselling alongside medication

✅  FACT-CHECK  All trial data sourced from published peer-reviewed literature. STEP 1: Wilding et al. (2021) NEJM [REF:1]. SELECT: Lincoff et al. (2023) NEJM [REF:2]. Trial registry: ClinicalTrials.gov NCT03548935 [REF:4]. Evidence Grade A reflects multiple large Phase 3 RCTs with consistent outcomes.

Blood Work to Monitor

Your GP should baseline and monitor the following before and during semaglutide use:

• HbA1c and fasting glucose — glucose management markers
• Lipid panel — cardiovascular risk markers (SELECT trial showed improvements)
• Pancreatic enzymes (lipase/amylase) — baseline and if abdominal pain occurs
• Thyroid function — baseline recommended given boxed warning
• Kidney function — particularly if pre-existing CKD
• Heart rate — semaglutide can increase resting heart rate modestly

Stacking — What Works and What to Avoid

Compatible combinations

• The Metabolic Stack (Semaglutide + AOD-9604): Fat loss via two non-competing pathways. AOD-9604 targets fat cells directly; semaglutide reduces appetite and total caloric intake. Commonly used together for body recomposition.
• CJC-1295 + Ipamorelin: GH secretagogue stack for muscle preservation during weight loss. Particularly relevant for athletes in a caloric deficit who want to avoid lean muscle loss.
• BPC-157: Gut support if GI side effects are persistent. Some practitioners use it to manage the GI burden during early semaglutide titration.

DO NOT combine with

⚠️  IMPORTANT  Never stack semaglutide with Tirzepatide, Retatrutide, Survodutide, or any other GLP-1 receptor agonist. Combining GLP-1 agonists produces severe GI toxicity with no additional therapeutic benefit. This is a serious risk — not a theoretical concern.

Who Semaglutide Is and Isn’t Right For

More likely to benefit

• Adults with BMI ≥30, or BMI ≥27 with a weight-related comorbidity (T2DM, hypertension, sleep apnea)
• Type 2 diabetes patients requiring blood sugar management alongside weight reduction
• People who have sustained dietary effort without meaningful results — particularly where appetite dysregulation is a factor
• Adults with elevated cardiovascular risk — SELECT trial showed 20% reduction in major CV events
• Athletes using it for body recomposition during a cutting phase (Segment 1 use case — not its primary indication)

Not recommended for

• Personal or family history of MTC or MEN2 — absolute contraindication
• History of pancreatitis
• Severe gastrointestinal disease or gastroparesis
• Pregnancy or planned pregnancy within 2 months
• Under 18 (for weight loss indication)
• Anyone seeking a short-term or ‘trial’ course — the evidence is clear that stopping reverses results

Experience level: Beginner. The auto-injector pen requires no reconstitution, no drawing up, no calculation. It is the most accessible delivery method of any injectable peptide on this site. The learning curve is the needle — not the compound.

References

• [1] Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183 (STEP 1 Trial — n=1,961)
• [2] Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. DOI: 10.1056/NEJMoa2307563 (SELECT Trial — n=17,604)
• [3] FDA. Ozempic (semaglutide) Prescribing Information. Approval 2017. Wegovy (semaglutide) Prescribing Information. Approval 2021. Available at fda.gov/drugs
• [4] ClinicalTrials.gov. STEP 1 — Efficacy and Safety of Semaglutide vs Placebo in Subjects with Obesity. NCT03548935. Phase 3, completed.
• [5] Therapeutic Goods Administration. Ozempic and Wegovy Product Information. TGA.gov.au. Schedule 4 Prescription Only Medicine. Verified 24/02/2026.
• [6] World Anti-Doping Agency. Prohibited List 2025. wada-ama.org/prohibited-list. Semaglutide: NOT listed. Accessed 24/02/2026.

Peptides Australia Editorial Team | Fact-checked: TGA Register + WADA 2025 Prohibited List | Last Reviewed: 24/02/2026

MEDICAL DISCLAIMER: This profile is for informational purposes only and does not constitute medical advice. Semaglutide is a Schedule 4 Prescription Only Medicine under Australian TGA regulations. A valid prescription from a registered Australian medical practitioner is required for legal access. Consult your GP or a registered specialist before use.